Table 3.
Association of EBF3 expression/promoter methylation with Kaplan-Meier survival in 105 pediatric AML samples
| Variable | No. of patients | Over survival | P |
|---|---|---|---|
| Median ± SE | |||
| Cytogenetics | |||
| Favorable | 50 | 46.664 ± 3.717 | <0.001 |
| Intermediate | 27 | 29.220 ± 3.188 | |
| Unfavorable | 28 | 11.161 ± 1.827 | |
| FAB | |||
| M1-M6 | 93 | 36.113 ± 2.885 | <0.001 |
| M7 | 12 | 8.542 ± 1.820 | |
| Leukocyte (/μl) | |||
| >10000 | 61 | 30.220 ± 2.974 | 0.803 |
| ≤10000 | 44 | 33.631 ± 4.063 | |
| MRD | |||
| <0.25% | 49 | 53.627 ± 3.151 | <0.001 |
| ≥0.25% | 56 | 18.893 ± 2.425 | |
| EBF3 expression | |||
| Low < 12.11 | 52 | 38.971 ± 4.402 | 0.091 |
| High ≥ 12.11 | 53 | 32.864 ± 3.654 | |
| EBF3 methylation | |||
| Negative | 60 | 35.143 ± 3.509 | 0.190 |
| Positive | 45 | 29.458 ± 2.607 |